IP Library › Granted Patent US 12,227,587
Granted Patent B2
US 12,227,587 · App. 18/415,419 · Granted Feb 18, 2025

Humanized complement 5A receptor 1 antibodies and methods of use thereof

Inventors: Karthik Viswanathan (Waltham, MA); Brian Booth (Waltham, MA); Boopathy Ramakrishnan (Waltham, MA); Andrew Wollacott (Waltham, MA); Gregory Babcock (Waltham, MA); Zachary Shriver (Waltham, MA); Lauren Olinski (Waltham, MA)
Assignee: Visterra, Inc.
C07K16/2896A61P37/02A61K2039/505C07K2317/24C07K2317/33C07K2317/52C07K2317/565C07K2317/76C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,227,587
App. No.
18/415,419
Granted
Feb 18, 2025
Kind
B2
Abstract

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

Claims (13)

1. A method of making an antibody or antigen binding fragment thereof that binds complement component 5a receptor 1 (C5aR1),

wherein the method comprises culturing a host cell comprising a nucleic acid encoding the C5aR1 antibody or antigen binding fragment thereof, and culturing the cell under conditions that allow production of the antibody or antigen binding fragment thereof,

wherein the C5aR1 antibody or antigen binding fragment thereof comprises a VH region, wherein the VH comprises three heavy chain complementarity determining regions (HCDRs), wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, respectively, and

a VL region, wherein the VL comprises three light chain complementarity determining regions (LCDRs), wherein the LCDR1, LCDR2, and LCDR3 sequences comprise the amino acid sequences of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, respectively.

2. The method of claim 1 , wherein the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 14.

3. The method of claim 2 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 14.

4. The method of claim 1 , wherein the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 25.

5. The method of claim 4 , wherein the VL comprises the amino acid sequence of SEQ ID NO: 25.

6. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 14; and wherein the VL comprises the amino acid sequence of SEQ ID NO: 25.

7. The method of claim 1 , wherein the antibody or antigen binding fragment thereof, further comprises a Fc region.

8. The method of claim 7 , wherein the Fc domain is independently selected from IgG1, IgG2, IgG3, and IgG4.

9. The method of claim 1 , wherein the antibody or antigen binding fragment is humanized.

10. The method of claim 1 , wherein the VH or the VL has been modified to enhance the stability of the molecule.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2024
From: VISWANATHAN, KARTHIK; BOOTH, BRIAN; RAMAKRISHNAN, BOOPATHY; WOLLACOTT, ANDREW; BABCOCK, GREGORY; SHRIVER, ZACHARY; OLINSKI, LAUREN
To: VISTERRA, INC.
Reel/Frame 066185/0817 →
Continuity (4)
Division 17575420 · Jan 13, 2022
Provisional Application 63274748 · Nov 2, 2021
Provisional Application 63137089 · Jan 13, 2021
Related Publication 20250002603A1 · Jan 2, 2025
References Cited (143)
US 5480974A · Morgan et al. · 1996 [cited by applicant]
US 7317091B2 · Lazar et al. · 2008 [cited by applicant]
US 7455837B2 · Guo et al. · 2008 [cited by applicant]
US 7632497B2 · Stavenhagen · 2009 [cited by applicant]
US 7863419B2 · Taylor et al. · 2011 [cited by applicant]
US 8071096B2 · MacKay · 2011 [cited by applicant]
US 8071839B2 · MacKay · 2011 [cited by applicant]
US 8084024B2 · MacKay · 2011 [cited by applicant]
US 8084582B2 · Dahiyat et al. · 2011 [cited by applicant]
US 8101720B2 · Lazar et al. · 2012 [cited by applicant]
US 8124731B2 · Lazar et al. · 2012 [cited by applicant]
US 8221757B2 · MacKay · 2012 [cited by applicant]
US 8268972B2 · Whitfeld et al. · 2012 [cited by applicant]
US 8318917B2 · Taylor et al. · 2012 [cited by applicant]
US 8337852B2 · MacKay · 2012 [cited by applicant]
US 8361468B2 · Whitfeld et al. · 2013 [cited by applicant]
US 8399618B2 · Lazar et al. · 2013 [cited by applicant]
US 8563259B2 · Lambris et al. · 2013 [cited by applicant]
US 8613926B2 · Kjaergaard et al. · 2013 [cited by applicant]
US 8673305B2 · MacKay · 2014 [cited by applicant]
US 8734791B2 · Lazar et al. · 2014 [cited by applicant]
US 8808701B2 · Whitfeld et al. · 2014 [cited by applicant]
US 8815237B2 · Wittrup et al. · 2014 [cited by applicant]
US 8846045B2 · Kjaergaard et al. · 2014 [cited by applicant]
US 8940299B2 · Medof et al. · 2015 [cited by applicant]
US 8952132B2 · Georgiou et al. · 2015 [cited by applicant]
US 8961967B2 · Strohl et al. · 2015 [cited by applicant]
US 8969526B2 · Baehner et al. · 2015 [cited by applicant]
US 9073983B2 · Guo et al. · 2015 [cited by applicant]
US 9180205B2 · Zeng et al. · 2015 [cited by applicant]
US 9458233B2 · Guo et al. · 2016 [cited by applicant]
US 9637549B2 · Strohl et al. · 2017 [cited by applicant]
US 9658236B2 · McKnight et al. · 2017 [cited by applicant]
US 9683050B2 · Zeng et al. · 2017 [cited by applicant]
US 9790268B2 · Pan et al. · 2017 [cited by applicant]
US 9890218B2 · Mimoto et al. · 2018 [cited by applicant]
US 10053513B2 · McCarthy et al. · 2018 [cited by applicant]
US 10183999B2 · Lazar et al. · 2019 [cited by applicant]
US 10323097B2 · Kjaergaard et al. · 2019 [cited by applicant]
US 10526408B2 · Georgiou et al. · 2020 [cited by applicant]
US 10590206B2 · Labrijn et al. · 2020 [cited by applicant]
US 10653791B2 · Lonberg et al. · 2020 [cited by applicant]
US 10774136B2 · Guo et al. · 2020 [cited by applicant]
US 10836813B2 · Pan et al. · 2020 [cited by applicant]
US 10882916B2 · Kjaergaard et al. · 2021 [cited by applicant]
US 10894836B2 · Stephen et al. · 2021 [cited by applicant]
US 11130801B2 · Medof et al. · 2021 [cited by applicant]
US 11142563B2 · Igawa et al. · 2021 [cited by applicant]
US 20040132101A1 · Lazar et al. · 2004 [cited by applicant]
US 20110002931A1 · Tamburini · 2011 [cited by applicant]
US 20180256646A1 · Medof et al. · 2018 [cited by applicant]
US 20180258161A1 · Igawa et al. · 2018 [cited by applicant]
US 20180282425A1 · Guo et al. · 2018 [cited by applicant]
US 20180319877A1 · Ruike et al. · 2018 [cited by applicant]
US 20190134020A1 · Deng et al. · 2019 [cited by applicant]
US 20190225708A1 · Bosteels et al. · 2019 [cited by applicant]
US 20190248897A1 · Ng et al. · 2019 [cited by applicant]
US 20190292269A1 · Monnet · 2019 [cited by applicant]
US 20190300621A1 · Ravetch et al. · 2019 [cited by applicant]
US 20200017598A1 · Andersson et al. · 2020 [cited by applicant]
US 20200095310A1 · Regula et al. · 2020 [cited by applicant]
US 20200131253A1 · Parren et al. · 2020 [cited by applicant]
US 20200148779A1 · Yamniuk et al. · 2020 [cited by applicant]
US 20200181257A1 · Kuramochi et al. · 2020 [cited by applicant]
US 20200199241A1 · Igawa et al. · 2020 [cited by applicant]
US 20200247897A1 · Jensen et al. · 2020 [cited by applicant]
US 20200299400A1 · Lonberg et al. · 2020 [cited by applicant]
US 20200316171A1 · Pandey · 2020 [cited by applicant]
US 20200332022A1 · Labrijn et al. · 2020 [cited by applicant]
US 20200376135A1 · Boitano et al. · 2020 [cited by applicant]
US 20210070860A1 · Marasco et al. · 2021 [cited by applicant]
US 20210070875A1 · Yang et al. · 2021 [cited by applicant]
US 20210238300A1 · Kjaergaard et al. · 2021 [cited by applicant]
US 20210261648A1 · Katada et al. · 2021 [cited by applicant]
US 20210285964A1 · McKnight et al. · 2021 [cited by applicant]
US 20220135658A1 · Neugebauer et al. · 2022 [cited by applicant]
US 20220356263A1 · Viswanathan et al. · 2022 [cited by applicant]
EP 1587540A2 · 2005 [cited by applicant]
EP 1443961B1 · 2009 [cited by applicant]
EP 1706424B1 · 2009 [cited by applicant]
EP 1701611B1 · 2011 [cited by applicant]
EP 2679681A1 · 2014 [cited by applicant]
EP 1476469B1 · 2015 [cited by applicant]
EP 2345671B1 · 2015 [cited by applicant]
EP 2940043A1 · 2015 [cited by applicant]
EP 2994488A1 · 2016 [cited by applicant]
EP 2506871B1 · 2016 [cited by applicant]
EP 2552955B1 · 2017 [cited by applicant]
EP 2673299B1 · 2017 [cited by applicant]
EP 2371861B1 · 2017 [cited by applicant]
EP 2486141B1 · 2018 [cited by applicant]
EP 2691417B1 · 2018 [cited by applicant]
EP 2718322B1 · 2018 [cited by applicant]
EP 3004174B1 · 2019 [cited by applicant]
EP 2844289B1 · 2019 [cited by applicant]
EP 3141260B1 · 2019 [cited by applicant]
EP 3541837A1 · 2019 [cited by applicant]
EP 3576793A1 · 2019 [cited by applicant]
EP 2943507B1 · 2020 [cited by applicant]
EP 3608339A1 · 2020 [cited by applicant]
EP 3630832A1 · 2020 [cited by applicant]
EP 3630833A1 · 2020 [cited by applicant]
EP 3424953B1 · 2020 [cited by applicant]
EP 2698431B1 · 2020 [cited by applicant]
EP 3768315A1 · 2021 [cited by applicant]
EP 3411400B1 · 2021 [cited by applicant]
JP 5162587B2 · 2013 [cited by applicant]
WO WO95000164 · 1995 [cited by applicant]
WO WO2004082568A3 · 2004 [cited by applicant]
WO WO2005050199A1 · 2005 [cited by applicant]
WO WO2008008482A2 · 2008 [cited by applicant]
WO WO2008022390A1 · 2008 [cited by applicant]
WO WO2009103113A1 · 2009 [cited by applicant]
WO WO2011100477A2 · 2011 [cited by applicant]
WO WO2012168199A1 · 2012 [cited by applicant]
WO WO2018065389A1 · 2018 [cited by applicant]
WO WO2018145075A1 · 2018 [cited by applicant]
WO WO2018183520A1 · 2018 [cited by applicant]
WO WO2018217988A9 · 2018 [cited by applicant]
WO WO2018218056A1 · 2018 [cited by applicant]
WO WO2018224609A1 · 2018 [cited by applicant]
WO WO2018234118A1 · 2018 [cited by applicant]
WO WO2019125846A1 · 2019 [cited by applicant]
WO WO2019183362A1 · 2019 [cited by applicant]
WO WO2020112781A1 · 2020 [cited by applicant]
WO WO2020182974A1 · 2020 [cited by applicant]
WO WO2021041715A2 · 2021 [cited by applicant]
WO WO2021146320A1 · 2021 [cited by applicant]
WO WO2021180063A1 · 2021 [cited by applicant]
WO WO2021190770A1 · 2021 [cited by applicant]
Akamizu, T. et al., “Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity”, Clinical & Experimental Immunology, vol. 127,… [cited by applicant]
Aniker-Ort et al: “Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway”, Frontiers in Immunology, vol. 11, Dec. 10, 2020. 20 pages. [cited by applicant]
Bekker, P. et al., “Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized… [cited by applicant]
Grayson, P. et al., “Antineutrophil Cytoplasmic Antibodies, Autoimmune Neutropenia, and Vasculitis”, Seminars in Arthritis and Rheumatism, vol. 42, Issue 3, Dec. 2011, pp. 424-433. [cited by applicant]
Huang et al: “Discovery of human antibodies against the C5aR target using phage display technology”, Journal of Molecular Recognition, Heyden & Son Ltd., London, GB, vol. 18, No. 4, Jun. 1, 2005 (Jun. 1, 2005), pp. 327-… [cited by applicant]
International Search Report and Written Opinion for PCT/US2021/013284, 13 pages (dated May 4, 2021). [cited by applicant]
International Search Report and Written Opinion for PCT/US2022/012317, 21 pages (dated Jun. 17, 2022). [cited by applicant]
Knight, A. et al., “Late-onset neutropenia after rituximab in ANCA-associated vasculitis”, Scandinavian Journal of Rheumatology, vol. 45, Issue 5, 2016. 5 pages. [cited by applicant]
Kussie et al., A single engineered amino acid substitution changes antibody fine specificity, 1994, The Journal of Immunology, vol. 152, Issue 1, pp. 146-152 (Year: 1994). [cited by applicant]
La-Crette, J. et al., “Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis”, Clin Rheumatol. 2018; 37(4): 1085-1090. [cited by applicant]
Melis, J. et al., “Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics”, Molecular Immunology, Vo. 67, No. 2, Part A, Oct. 2015, pp. 117-130. [cited by applicant]
Ohlsson, S. et al., “Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation”, PLoS One 14(6): e0218272. 16 pa… [cited by applicant]
Rudikoff et al: “Single amino acid substitution altering antigen-binding specificity”, Proceedings of the National Academy of Sciences, National Academy of Sciences, vol. 79, No. 6, Mar. 1, 1982 (Mar. 1, 1982), pp. 1979… [cited by applicant]